PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|August 2, 2003
- Pharmaceutical Technology-08-02-2003
- Volume 27
- Issue 8
The Influence of Pregelatinized Starch Disintegrants on Interacting Variables that Act on Disintegrant Properties
Author(s)Gbenga Alebiowu
This study evaluates the quantitative effects of the nature and concentrations of disintegrants and a tablet's relative density on disintegrant properties such as disintegration time and the crushing strength-friability/disintegration time ratio.
Advertisement
Articles in this issue
about 23 years ago
BIO Updateabout 23 years ago
Designing Transfer Carts for Class 100 Conditionsabout 23 years ago
An Update on Osmotic Drug Deliveryabout 23 years ago
New FDA Initiatives Aim to Spur Innovationabout 23 years ago
Interphex Serves as a Showcase for New Materials and Machinesabout 23 years ago
August 2003about 23 years ago
In the Spotlight August 2003Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement